| |
Wednesday, April 2, 2025 | 11:00 AM ET
Get expert strategies for validating robust, scalable immunogenicity assays to reduce costs and minimize rework from early trials to market.
Register now. +(002)+140w+(3).png)
|
|
Today’s Big NewsApr 2, 2025 |
|
Tuesday, April 8, 2025 | 1pm ET / 10am PT Learn how AI-powered digital phenotyping and real-world data (RWD) help identify overlooked patient populations, bridge gaps between clinical guidelines and real-world treatment, and refine commercial strategies. Join experts to discover how AI-driven insights can optimize market positioning and ensure therapies reach the right patients. Register now! 
|
|
| By Gabrielle Masson The FDA’s Chief Medical Officer Hilary Marston, M.D., is leaving her position at the agency amid huge cuts to staff across the FDA. |
|
|
|
By Gabrielle Masson Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech’s gene therapy designed to reverse or prevent blindness through a potential market approval. |
By Darren Incorvaia Flagship Pioneering-backed Sail Biomedicines has laid off 12 employees following a review of the company’s organizational structure, a Sail spokesperson confirmed in an email to Fierce Biotech, leaving 125 staff still employed. |
Sponsored by Allucent Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how sponsors can align with FDA expectations and implement more precise dose-finding strategies. Watch the full interview with Alex MacDonald now! |
|
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
By Nick Paul Taylor Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable transcription factor. |
By James Waldron Edgewise Therapeutics' hypertrophic cardiomyopathy asset has resulted in “rapid and clinically meaningful” reductions of a measure of obstruction of the heart’s valves. |
By James Waldron Analysts appeared unfazed by the news that a patient treated with Cabaletta Bio’s autoimmune CAR-T suffered a toxicity complication during a phase 1/2 trial. |
By Darren Incorvaia AstraZeneca and the Memorial Sloan Kettering Cancer Center have tapped digital health tech company IgniteData to provide an automated data capture tool for a phase 3 clinical trial. |
By Kevin Dunleavy A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity disorder, Axsome Therapeutics has unveiled mixed results for the same compound in a study in patients with major depressive disorder. |
By Darren Incorvaia Two investment firms have acquired large stakes in global CRO Novotech, the Singapore-based company announced March 30. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 11am ET / 8am PT Copay programs are designed to make treatments more affordable, but too often, patients don’t know they exist or how to use them. That means financial assistance goes unused, medications go unfilled, and patients face unnecessary barriers to starting and staying on treatment. Join us to learn how to move beyond outdated, manual copay distribution methods. Register now. |
|
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
